Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
Christopher R. King,Debra Freeman,Irving D. Kaplan,Donald B. Fuller,Giampaolo Bolzicco,Sean P. Collins,Robert J. Meier,Jason Wang,Patrick A. Kupelian,Michael L. Steinberg,Alan W. Katz +10 more
Reads0
Chats0
TLDR
PSA relapse-free survival rates after SBRT compare favorably with other definitive treatments for low and intermediate risk patients, and the current evidence supports consideration of S BRT among the therapeutic options for these patients.About:
This article is published in Radiotherapy and Oncology.The article was published on 2013-11-01 and is currently open access. It has received 394 citations till now. The article focuses on the topics: PSA Failure & Androgen deprivation therapy.read more
Citations
More filters
Journal ArticleDOI
Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Robert T. Dess,William C. Jackson,Simeng Suy,Payal D. Soni,Jae Y. Lee,Ahmed E. Abugharib,Zachary S. Zumsteg,Felix Y. Feng,Daniel A. Hamstra,Sean P. Collins,Daniel E. Spratt +10 more
TL;DR: The authors assessed the incidence and predictors of a global decline in health‐related quality of life (HRQOL) after prostate SBRT.
Journal ArticleDOI
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT).
Yasir Alayed,Harvey Quon,Aldrich Ong,Patrick Cheung,William Chu,Hans Chung,Danny Vesprini,Amit Chowdhury,Dilip Panjwani,Geordi Pang,Renee Korol,Melanie Davidson,Ananth Ravi,Boyd McCurdy,Liying Zhang,Alexandre Mamedov,Andrea Deabreu,Andrew Loblaw,Andrew Loblaw +18 more
TL;DR: Although it was previously reported that weekly prostate SABR had better bowel and urinary QOL compared to EOD, the updated results show no difference in late toxicity, QOL, BF, or PSA kinetics.
Journal ArticleDOI
Robotic ultrasound-guided SBRT of the prostate: feasibility with respect to plan quality
Stefan Gerlach,Ivo Kuhlemann,Philipp Jauer,Ralf Bruder,Floris Ernst,Christoph Fürweger,Alexander Schlaefer +6 more
TL;DR: The results indicate that a careful choice of the ultrasound robot’s pose and a large solid angle covered by beam starting positions can offset this effect of blocking of beam directions and identify robot poses that yield acceptable plan quality and allow for intra-fraction ultrasound image guidance.
Journal ArticleDOI
Prostate-specific antigen kinetics after primary stereotactic body radiation therapy using CyberKnife for localized prostate cancer.
Yong Hyun Park,In Young Choi,Sei Chul Yoon,Hong Seok Jang,Hyong Woo Moon,Sung-Hoo Hong,Sae Woong Kim,Tae-Kon Hwang,Ji Youl Lee +8 more
TL;DR: PSA decline occurred rapidly in the first month, and then the rate of PSA decline fell off steadily over time throughout 2 years after treatment, indicating that SBRT using CyberKnife leads to long-term favorable BCR-free survival in localized prostate cancer.
Journal ArticleDOI
Evaluating the Tolerability of a Simultaneous Focal Boost to the Gross Tumor in Prostate SABR: A Toxicity and Quality-of-Life Comparison of Two Prospective Trials.
Yasir Alayed,Melanie Davidson,Stanley K. Liu,William Chu,Eric Tseng,Patrick Cheung,Danny Vesprini,Hans Cheung,Gerard Morton,Hima Bindu Musunuru,Anath Ravi,Renee Korol,Andrea Deabreu,Ling Ho,Kristina Commisso,Zeeba Bhounr,Laura D'Alimonte,Nicole Mittmann,Alice Dragomir,Liang Zhang,Andrew Loblaw +20 more
TL;DR: Prostate and pelvic XXXX with a simultaneous DIL boost was feasible and acute grade ≥2 toxicity, late toxicity, and QOL seems to be comparable to a cohort that did not receive a focal boost, and further follow-up will be required to assess long-term outcomes.
References
More filters
Journal ArticleDOI
Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
TL;DR: Significant late bladder and rectal toxicities from SBRT for prostate cancer are infrequent and the current evidence supports consideration of stereotactic body radiotherapy among the therapeutic options for localized prostate cancer.
Journal ArticleDOI
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience.
TL;DR: The outcomes after high-dose hypofractionation were acceptable in the entire cohort of patients treated with the schedule of 70 at 2.5 Gy/fraction and the 5-year nadir + 2 ng/mL rate was 83% (95% confidence interval, 79–86%).
Journal ArticleDOI
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
TL;DR: In this paper, the feasibility and toxicity of stereotactic hypofractionated accurate radiotherapy (SHARP) for localized prostate cancer were evaluated in a Phase I/II trial with 40 patients.
Journal ArticleDOI
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
Himu Lukka,Charles Hayter,Jim A. Julian,Padraig Warde,W. James Morris,Mary Gospodarowicz,Mark Levine,Jinka Sathya,Richard Choo,Hugh M. Prichard,Michael Brundage,Winkle Kwan +11 more
TL;DR: This study was designed as a noninferiority investigation with a predefined tolerance of −7.5%.
Journal ArticleDOI
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial
David P. Dearnaley,Isabel Syndikus,Georges Sumo,M. Bidmead,D. Bloomfield,Catharine H. Clark,Annie Gao,Shama Hassan,Alan Horwich,Robert Huddart,Vincent Khoo,Peter Kirkbride,Helen Mayles,P. Mayles,O. Naismith,Chris Parker,Helen Patterson,Martin J. Russell,Christopher D Scrase,C. South,John Staffurth,Emma Hall +21 more
TL;DR: A pre-planned preliminary safety analysis of side-effects in stages 1 and 2 of a randomised trial comparing standard and hypofractionated radiotherapy seems equally well tolerated as conventionally fractionated treatment at 2 years.
Related Papers (5)
Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
David P. Dearnaley,Isabel Syndikus,Helen Mossop,Vincent Khoo,Alison Birtle,D. Bloomfield,John Graham,Peter Kirkbride,John P Logue,Zafar Malik,Julian Money-Kyrle,Joe M. O'Sullivan,Miguel Panades,Chris Parker,Helen Patterson,Christopher D Scrase,John Staffurth,Andrew Stockdale,Jean Tremlett,M. Bidmead,Helen Mayles,O. Naismith,C. South,Annie Gao,Clare Cruickshank,Shama Hassan,Julia Pugh,Clare Griffin,Emma Hall +28 more
Fractionation and protraction for radiotherapy of prostate carcinoma
David J. Brenner,Eric J. Hall +1 more